Podcasts about pharmaceuticals

Long before cancer survivors organized into a movement, Hollywood had already shaped how Americans understood the disease. Films rarely used the word “cancer,” physicians often withheld diagnoses from patients, and the people who survived were almost nowhere to be found on screen.Recorded before The Cancer Mavericks: A History of Survivorship became a documentary series, this bonus conversation explores where the project first began. Matthew Zachary sits down with his mother, Roz Greenzweig, a retired educator and lifelong film enthusiast whose memories of classic cinema became an unexpected lens for understanding how cancer was portrayed throughout the twentieth century.Together, they revisit landmark films including Dark Victory, Love Story, and other iconic portrayals that reflected an era when cancer was treated as unspeakable, inevitable, and almost always fatal. Their conversation contrasts those carefully constructed Hollywood narratives with the lived reality of a family confronting a brain cancer diagnosis in 1995, revealing how popular culture both reflected and reinforced the fears surrounding the disease.The discussion also foreshadows many of the themes explored throughout the documentary series: the evolution of patient advocacy, the emergence of cancer survivorship, the role of caregivers, and the power of storytelling to influence public understanding. Before policy changed, before advocacy organizations grew into national movements, conversations like these were already challenging long-held assumptions about what cancer looked like and who had the right to tell its story.Consider this the prologue to The Cancer Mavericks. Before the movement found its history, it began with a family trying to make sense of the stories they had inherited.RELATED LINKSAmerican Cancer Society⁠National Cancer Institute⁠American Film Institute⁠ER (NBC)⁠50/50 (Official)⁠Chasing Life (ABC Family Archive)⁠FEEDBACKLike this episode? Rate and review The Cancer Mavericks: A History of Survivorship on your favorite podcast platform. For more information, visit CancerMavericks.com. Questions? Email podcasts@matthewzachary.com.See Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What happens when a first-generation entrepreneur who's transformed 500+ brands sits down to expose pharma's biggest secret? Creative Mediocrity.In this explosive conversation, Aleem Merchant—TEDx speaker, 40under40 winner, and founder of Synapse (one of India's most respected award-winning agencies)—reveals why the pharmaceutical industry refuses to innovate and how playing it safe has become the most dangerous strategy.With over two decades of experience working with the world's best brands across FMCG, luxury, IT, and his specialty—Healthcare & Pharmaceuticals—Aleem shares the uncomfortable truths that pharma marketers know but won't say out loud.ABOUT ALEEM MERCHANT:Aleem is a brand consultant, thought-leader, creative marketeer, digital marketing pro, author, blogger, and podcaster—all rolled into one. As the Founder and Director of Synapse, he's built one of India's most respected advertising and marketing agencies.His philosophy: Creativity isn't just craft—it's the solution to business problems and market opportunities. He's consulted and created strategies for 500+ brands, earning international awards and the trust of leading companies across industries.His expertise in Healthcare and Pharmaceuticals makes this conversation especially powerful—he's seen firsthand what works, what doesn't, and why pharma keeps choosing mediocrity.PERFECT FOR:Pharma marketers & CMOsHealthcare marketing professionalsBrand strategists in regulated industriesAgency professionalsEntrepreneurs in healthcare/pharmaAnyone frustrated with industry conservatismIf this conversation challenged your thinking, hit LIKE and SUBSCRIBE for more industry-disrupting conversations.Connect with Aleem -  / aleemmerchant  Connect with Lokesh -  / lokesh-sharma-7250a71a9  Follow us on social media - Website : https://gameofpharma.com/Instagram : https://www.instagram.com/gameofpharm...LinkedIn :  / game-of-pharma-podcast  

"We have an untapped army of 200,000 PAs that really could step up and drive some change in the healthcare system if we weren't restricted,” says Dr. Jennifer Kolb, capturing her motivation for pushing to update practice regulations for physician associates that date back more than 50 years.  As Chief Medical Officer and Senior Vice President of Clinical Affairs at the American Academy of Physician Associates, Dr. Kolb has been in the middle of the fight at the state and federal level to grant PAs more independence from physicians, full billing rights, and the increased ability to practice across state lines, among other changes.  In this pertinent conversation with Raise the Line host Lindsey Smith, Dr. Kolb explains how these updates could help close huge gaps in access to healthcare, better manage the fight against chronic diseases and improve patient outcomes.   Dr. Kolb also addresses:  Why the name shift from "assistant" to "associate" took her years to fully appreciate; How a 10-year gap in life expectancy across Chicago zip codes shapes her view of health equity; Why PA's shouldn't wait for permission to start making change in their communities. Mentioned in this episode:American Academy of Physician Associates   If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Rebecca Bloom is a former employee benefits and executive compensation attorney who spent more than 25 years helping women navigate cancer, work, insurance, disability coverage, and financial survival. She is the founder and author of When Women Get Sick, a book built from decades inside the legal, workplace, and patient advocacy systems most people only discover after diagnosis.Bloom started in Big Law at Simpson Thacher handling employee benefits and compensation work she originally chose to pay off student loans. Then her mother was diagnosed with breast cancer. Suddenly the language she used in corporate law offices became the language of survival at home. Explanation of benefits forms. Coverage disputes. Second opinions. Disability protections. Medical leave. Bills no one could explain.That collision changed the direction of her life.In this episode, Bloom explains how serious illness quietly turns patients into unpaid administrators managing paperwork, logistics, financial risk, and emotional labor while trying to survive treatment. She breaks down how employer based health insurance shapes nearly every aspect of cancer care in America and why women often carry the invisible burden of protecting everyone else from discomfort while they themselves fall apart.The conversation digs into workplace power, the illusion of the healthcare “safety net,” caregiver exhaustion, and the class divide hiding underneath patient empowerment culture. Bloom explains why educated, insured women with resources still struggle to navigate healthcare bureaucracy and what happens to patients without those advantages.This episode explores cancer care, health insurance, employee benefits, patient advocacy, workplace protections, caregiving, and the structural incentives that force sick people to become project managers of their own survival.RELATED LINKSRebecca BloomWhen Women Get SickBay Area Cancer ConnectionsSimpson Thacher & BartlettFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Plus: Apple approaches $5 trillion market cap. And AstraZeneca says it's on track to hit its revenue target for 2030. Imani Moise hosts. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

With hospitals facing increasing drug company restrictions on access to 340B savings and other challenges, some might be considering opening their own retail pharmacies to serve their patients. We speak with Sherstin Willyerd, director of pharmacy operations at Montgomery County Memorial Hospital in Iowa, to learn about how her hospital went this route and what others want to consider before doing the same. Buying Existing Pharmacies Can Be a Solution Willyerd said her hospital was able to purchase two independent pharmacies whose owners were retiring, providing an existing dispensing infrastructure and patient base from which to start. While the hospital still has some contract pharmacy partnerships, the in-house locations can serve patients and generate 340B savings that are less prone to drugmaker restrictions.A Retail Pharmacy Can Give Better Insight into Patient StrugglesOperating a retail pharmacy allowed Willyerd's hospital to see more clearly which patients were struggling with prescription drug costs and medication adherence and to provide more assistance to them. She noted that capturing more 340B savings makes it easier to pass along more discounts to patients who otherwise would not be able to afford their drugs.An Independent Insurance Plan Means Even More AssistanceMontgomery County Memorial Hospital also partnered with a pharmacy benefit manager (PBM) to create a primary and secondary prescription drug insurance plan that it offers to certain patients with low incomes and hospital employees. Willyerd noted that this plan can mean hundreds of dollars in savings per month for uninsured patients and those whose coverage comes with high cost sharing.Resources:HRSA Releases 340B Purchase Data for 2025

Most adults who smoke want to quit, and about half try to do so in any given year, yet fewer than one in ten succeed. That persistent gap between intention and outcome is one of the central challenges in public health, and it's exactly the kind of problem that calls for new thinking about how to communicate with people to support behavior change.  Dr. Amanda Graham has been a leading force in doing just that in her role as chief health officer at Truth Initiative, the nation's largest non-profit public health organization dedicated to preventing addiction among young people and helping people of all ages to quit tobacco. On this episode of Raise the Line from Elsevier, Dr. Graham, who holds a PhD in clinical health psychology and has done 25 years of NIH-funded research focused on technology-based cessation interventions, helps us understand the interplay between behavioral science and digital communications in the field. "A well-timed message can really be powerful in interrupting what for many people is kind of an automatic behavior, especially via text, which data tell us is an extraordinarily powerful modality,” she explains to host Lindsey Smith.  Tune-in to understand where the field is heading, and to learn about: Why "push" technology may work better than apps and websites when it comes to breaking automatic behaviors; How the rise of e-cigarettes, nicotine pouches, and heated tobacco has scrambled decades of public health messaging; How highschool smoking rates plunged from over 30% to less than 2%. Mentioned in this episode: Truth Initiative Program with Mayo Clinic If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Super Bowl-winning quarterback and 2026 Pro Football Hall of Fame inductee Drew Brees talks about participating in an awareness campaign to promote ARS Pharmaceuticals' emergency allergy spray, Neffy.  SHOW DESCRIPTION LONGDrew Brees can add pharma brand spokesperson to his already impressive résumé. This week's episode features executive editor Jack O'Brien in conversation with the Super Bowl-winning quarterback and 2026 Pro Football Hall of Fame inductee.  Brees talks about how he got involved with ARS Pharmaceuticals on its Neffy awareness campaign, his own journey as an allergy patient, how this medical marketing work compares to other ad campaigns he's participated in (such as that Pepsi commercial featuring One Direction) and even indulges in a little football talk. Check us out at: mmm-online.com Follow us: YouTube: @MMM-onlineTikTok: @MMMnewsInstagram: @MMMnewsonlineTwitter/X: @MMMnewsLinkedIn: MM+M To read more of the most timely, balanced and original reporting in medical marketing, subscribe here.Music: “Deep Reflection” by DP and Triple Scoop Music. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Synopsis: In an industry often defined by rapid innovation and high-stakes science, long-term success in biotech requires more than breakthrough discoveries—it demands strategic clarity, resilient leadership, and a deep understanding of unmet patient needs. In this engaging conversation, Rahul Chaturvedi sits down with Robert Jacks, President & CEO of Sparrow Pharmaceuticals, to explore his unconventional journey from civil engineering to biotech leadership, the lessons learned from building and exiting successful companies, and why creating lasting value should take precedence over chasing acquisitions. Robert reflects on his career spanning Pfizer, entrepreneurship, venture capital at OrbiMed, and leading multiple biotech companies, sharing how his experiences shaped his approach to leadership, capital allocation, and company building. He explains why influence matters more than authority, how empathy creates stronger organizations, and why keeping biotech companies lean allows them to remain resilient throughout unpredictable funding cycles. The conversation then explores Sparrow Pharmaceuticals' evolution from a rare disease company into a precision medicine leader focused on difficult-to-control type 2 diabetes. Robert provides an in-depth look at the emerging science behind cortisol biology, HSD1 inhibition, and why excess intracellular cortisol may represent one of the industry's most overlooked drivers of metabolic disease. He also discusses Sparrow's recent clinical data, the rationale behind its strategic pivot, the future of patient stratification in cardiometabolic disease, and how Sparrow aims to complement—not compete with—the rapidly expanding GLP-1 landscape. From fundraising and leadership philosophy to clinical development strategy and the next frontier of precision medicine, this episode offers practical insights for biotech founders, investors, and industry leaders navigating the complexities of building enduring biotech companies. Biography: Robert has 25 years of experience in the biopharmaceutical industry. He has founded or co-founded multiple companies and raised more than $300 million. Previously, Robert was the President & CEO of Indalo Therapeutics, a clinical-stage biotechnology company developing therapeutics for serious fibrotic diseases, and President, CFO, and Co-Founder of Symbiomix Therapeutics, which was sold after achieving NDA approval for Solosec®. Robert also previously held the positions of Head of Corporate Development for Tobira Therapeutics, Head of Business Development for ACT Biotech, and Entrepreneur-in-Residence for OrbiMed Advisors. Robert began his pharmaceutical industry career in finance and product development at Pfizer, where he last worked as the Director of Business Development for Oncology and Infectious Diseases. Robert earned an MBA from Columbia Business School, an MSE in Civil Engineering from Stanford University, and a BSE in Civil Engineering from Duke University. When not solving intractable healthcare problems, Robert spends as much time as possible with his two daughters.

Plus: Oil tops $90 a barrel as Middle East conflict continues. And shares of Utz Brands soar after the snack-food maker agrees to go private. Imani Moise hosts. Sign up for WSJ's free What's News newsletter. An artificial-intelligence tool assisted in the making of this episode by creating summaries that were based on Wall Street Journal reporting and reviewed and adapted by an editor. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Plus: Carl Icahn's company agrees to sell auto-service chain Pep Boys. And Ukraine strikes a deal with defense company BAE Systems to manufacture howitzers locally. Alex Ossola hosts. Sign up for WSJ's free What's News newsletter. An artificial-intelligence tool assisted in the making of this episode by creating summaries that were based on Wall Street Journal reporting and reviewed and adapted by an editor. Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Vasanta Pundarika built her career inside healthcare investment banking before launching Lotuspring, an advisory firm focused on women's health and behavioral health. She spent nearly 20 years advising healthcare systems, treatment providers, and growth stage companies on mergers, financing, and operational strategy while watching the industry repeatedly misunderstand the people it claimed to serve.The conversation starts unexpectedly with anthropology, bread, and language. Vasanta explains how she spent years changing the pronunciation of her own name to make other people comfortable before eventually reclaiming it. That thread opens into a much larger discussion about adaptation, identity, and what institutions quietly train people to tolerate.From there, the discussion moves into behavioral health, women delaying care, and the invisible labor that healthcare business models routinely ignore. During COVID, Vasanta noticed men's behavioral health units refilled faster than women's units. The reason had nothing to do with demand. Women were still home managing caregiving responsibilities, children, aging parents, and households while their own mental health collapsed in the background.The episode examines what happens when healthcare companies become “snazzy big brands” before building real clinical substance underneath. Vasanta describes the tension between mission and margin inside healthcare startups, private equity backed care models, and behavioral health expansion. The conversation pushes on who benefits when healthcare scales aggressively, who absorbs the operational pressure, and how patient trust erodes long before executives notice it on a dashboard.They also discuss patient advocacy culture, anthropology as systems analysis, healthcare capitalism, prior authorization, investor language, and why some clinically excellent companies never survive long enough to scale.RELATED LINKSVasanta PundarikaLotuspringWomen's Health HorizonsSakhi for South Asian SurvivorsNACDPrinceton University Anthropology DepartmentFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

"I always remember feeling like I was part of the clean plate club," says Dr. Christle Guevarra, recalling a childhood spent quietly convinced that her weight was a matter of willpower. That belief followed her through a competitive powerlifting career and medical practice until she finally tried a GLP-1 medication herself and, as she describes it, the constant mental noise around food quieted down. Now a board-certified family and sports medicine physician, traveling team doctor for U.S. Figure Skating, and author of The Beginner's Guide to GLP-1s, Dr. Guevarra brings a rare combination of clinical authority and lived experience to the conversation around obesity medicine.  In this episode of Raise the Line from Elsevier, host Lindsey Smith talks with her about what's actually changed in how physicians understand the issue and what it means for patients. "The biggest thing is reframing how we approach weight loss. It's not just a willpower problem, it is a neurobiological problem." Tune in to learn about: Why she said no to a GLP-1 prescription for two years and what finally changed her mind; The real story behind concerns about muscle loss on these medications; What happens when the “food noise" goes silent and a new set of challenges takes its place.   Mentioned in this episode:  Dr. Christle's website If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

The following article of the Health  industry is: “The Three Pillars of Diagnosis in Rare Diseases” by David López García, Former Managing Director for Mexico and CAAC Region, BioMarin Pharmaceuticals México.

Brad Power spent years advising major corporations on systems design, process engineering, and decision making before lymphoma shoved him into the patient side of American healthcare. Instead of accepting the experience at face value, he started reverse engineering the machinery around cancer itself. Brad is the founder of Cancer Patient Lab and Open Cancer AI, two projects built around a blunt reality most patients discover too late: the healthcare system rewards people who know how to navigate it. Everyone else risks getting steamrolled by information asymmetry, insurance barriers, administrative friction, and institutional incentives designed around efficiency instead of human survival.The conversation starts with Harvard Business Review and Tumblr blogs before moving directly into the darker architecture underneath modern cancer care. Power explains how hospitals optimize for throughput, how insurance companies reward operational consistency over personalized medicine, and why many patients quietly end up needing a crash course in oncology, reimbursement policy, and behavioral psychology while fighting for their lives.The discussion digs into CAR-T therapy, functional testing, AI assisted decision support, and the growing collision between personalized medicine and standardized care pathways. Power argues that engaged patients often get better outcomes because they learn how to push for off guideline treatments, contest denials, and ask smarter questions. The counterpoint lands hard: patients should never have needed to become experts in the first place.The episode also explores the cultural consequences of AI entering cancer care. OpenAI advertising, data privacy, trust erosion, pharmaceutical influence, and “agentic AI” all collide inside a healthcare economy already drowning in distrust. Power sees artificial intelligence as a force multiplier for patient literacy and access. The larger system still decides who gets approved, who gets delayed, and who gets left behind.By the end, the conversation lands exactly where modern healthcare keeps forcing people to land: survival increasingly depends on learning how the machine works before the machine works on you.RELATED LINKSBrad PowerCancer Patient LabOpen Cancer AIHarvard Business ReviewResearch to the PeopleCAR T Cell TherapyFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

After years of lobbying and advocacy work by 340B covered entities, the Illinois state legislature approved major 340B legislation earlier this year that protects 340B contract pharmacy access and prohibits drugmaker claims on data demands. Thomas Yu, system director of ambulatory pharmacy services at Sinai Chicago, discusses the campaign that made this legislative victory possible and what covered entities in other states can learn from this success.Joint Events Showed Unity Among Safety-Net ProvidersYu says two “340B Saves Lives” days of action in Chicago helped drive support for the legislative effort. Under the leadership of an association representing community health centers, the events brought together covered entities, patients, lawmakers, and others to show a united front on the issue of protecting 340B.The Story of 340B Resonated With Lawmakers, Not Numbers AloneYu reiterates that statistics and data can be helpful in making the case for 340B but that the story of 340B is what can swing votes. Focusing on community impact and how covered entities use their savings to benefit patients was much more effective at imparting the importance of legislation to protect access to those savings.Illinois Legislation Was a Compromise The legislation package in Illinois contains 340B reporting requirements for covered entities in the state. Yu argues that this compromise was necessary as the contract pharmacy and claims data provisions would have been a “nonstarter” without that addition. However, because the numbers go to the state for a one-time report and because drugmakers also must report data, he says the overall legislative package still makes for a big win for covered entities and patients in the state.ResourcesIllinois Legislature Delivers Contract Pharmacy Victory for 340B HospitalsProposed Medicare Pay Cut for 340B Drugs Would Be Much Deeper Than 2018-2022 Reductions

By the time the paper hit version 71, Dr. Nirosha Murugan had already done the hard part. The data were real. The experiment had worked. A team of researchers had used a wearable bioreactor to trigger limb regeneration in frogs, a result with obvious implications for regenerative medicine. But the science still wasn't getting over the line. The problem wasn't the work. It was the translation.On this episode of Standard Deviation, host Oliver Bogler talks with Dr. Nirosha Murugan, a biophysicist and Tier II Canada Research Chair in Tissue Biophysics at Wilfrid Laurier University, about what happens when a scientist working at the edges of quantum biology, bioelectricity, and tissue regeneration runs headfirst into the unwritten rules of academic publishing. Murugan's research asks biologists to think beyond molecules and chemistry alone, and to consider the physical signals, electromagnetic fields, and invisible forces that shape development and healing. It is ambitious science. It is also exactly the kind of work that can make gatekeepers nervous.Bogler follows Murugan through the less glamorous part of discovery: the hidden curriculum of getting a paper published, securing scientific credibility, and learning that data do not simply “speak for themselves.” Murugan describes how jargon buried the pitch of her own work, how a lack of editorial support left her at a disadvantage, and how the JEDI program at the Life Science Editors Foundation paired her with a former journal editor who taught her how to structure a manuscript, write a cover letter, and survive peer review.The result was publication in Science Advances, but the larger story is about power. Who gets taught the rules of biomedical research. Who has access to grant writers, editors, and institutional polish. Who is left to brute-force their way through the maze. And how one scientist, having finally found the map, now makes sure her own trainees do not have to learn it the hard way.RELATED LINKSDr. Nirosha Murugan⁠Wilfrid Laurier University⁠Life Science Editors Foundation⁠JEDI Program⁠Science Advances paper on limb regeneration⁠FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Millions of Americans were saddened and outraged by the Sandy Hook Elementary shooting in 2012 that took the lives of twenty children and six adults, and were left feeling helpless about the epidemic of gun violence in the U.S. that, sadly, continues to this day. But for our guest today, Shannon Watts, her feelings of devastation about the shooting turned to rage and fueled her unlikely rise to leading Moms Demand Action, which she grew into one of the largest grassroots organizations in the country, mobilizing millions of volunteers to push for stronger gun safety laws. “I wanted to stand shoulder to shoulder with a badass army of women because that's who gets things done in this country,” she says.    In this inspiring conversation with Raise the Line host Michael Carrese, Watts pulls back the curtain on how the group achieved its successes and the philosophy of "losing forward" that kept volunteers showing up year after year. In her recent book Fired Up, Watts describes how she is bringing insights from that experience to a new mission: helping women identify their values, abilities, and desires and acting on them without waiting until everything is perfect. Tune-in to learn about:  The "false fires" women mistake for passion; Why losing estrogen and testosterone in midlife might actually make women braver, not less so; The one exercise she does with every woman she coaches.  Mentioned in this episode: Fired Up book Moms Demand Action If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

What if the pills in your medicine cabinet are the problem, not the fix? Dr. Robert Beltran was a triple board-certified surgeon and pharmacist for 30 years. Then a 2014 accident left him dependent on OxyContin. A five-herb blend from an Asian market cleared his brain fog in three weeks and got him off opioids, launching a decade of formulating plant-based supplements at recomnd Nutrition. Meet our guest Dr. Robert Beltran (MD, PharmD, FACS) is a retired ENT and cosmetic surgeon and the CEO and Chief Formulator of recomnd Nutrition. At 73, he blends a pharmacist's rigor with a decade of clinical work on herbal formulas for cognition, stress, and sexual wellness. Thank you to our partners Outliyr Biohacker's Peak Performance Shop: get exclusive discounts on cutting-edge health, wellness, & performance gear Ultimate Health Optimization Deals: a database of of all the current best biohacking deals on technology, supplements, systems and more Latest Summits, Conferences, Masterclasses, and Health Optimization Events: join me at the top events around the world FREE Outliyr Nootropics Mini-Course: gain mental clarity, energy, motivation, and focus Key takeaways A 2024 DNA barcoding study found 60% of shelf supplements don't match their label At least half of market supplements show no measurable benefit No clinical study has shown an obvious anti-aging benefit from NAD, per Beltran Herbs like tongkat ali and maca raise the body's own testosterone without replacing it 70% of men on testosterone therapy over 12-18 months develop side effects Antidepressants, sedatives, and sleep aids account for 60,000 deaths a year Fix exercise, diet, and stress before reaching for any supplement Episode highlights 01:53 The accident and the opioid trap 04:43 The five-herb blend that changed everything 07:01 What extract ratios really mean 18:31 The case against NAD 28:26 Herbs that raise testosterone naturally 30:55 The testosterone therapy risks clinics bury 49:15 The 60,000-death problem 53:26 Three desert-island ingredients 01:01:22 What to fix before any supplement   Links Watch it on YouTube: Full episode show notes: https://outliyr.com/268  Connect with Nick on social media Instagram Twitter (X) YouTube LinkedIn Easy ways to support Subscribe Leave an Apple Podcast review Suggest a guest Do you have questions, thoughts, or feedback for us? Let me know in the show notes above and one of us will get back to you! Be an Outliyr, Nick

Send us Fan MailWhy does one person become severely ill from mold exposure while everyone else in the house seems fine?In this episode of Never Been Sicker, Michael Rubino sits down with holistic physician Dr. Michael Biamonte to explore the often-overlooked connection between mold illness, Candida overgrowth, gut health, toxic metals, parasites, and chronic inflammation.Dr. Biamonte explains why mold recovery isn't just about remediating your home. He discusses how gut dysbiosis, leaky gut, biofilms, and weakened immune function can make certain people far more susceptible to environmental toxins. The conversation also dives into long COVID, spike protein, heavy metals, personalized nutrition, pharmaceutical side effects, and why treating symptoms alone often isn't enough.Whether you're struggling to recover from mold exposure or searching for the root cause of chronic illness, this episode offers a comprehensive look at how your environment and your body work together.-----------------------------------------------------------------------------------------------CHAPTERS:00:00 Introduction01:02 Meet Dr. Michael Biamonte02:10 Why Some People Get Sick From Mold05:20 Candida, Gut Health & Mold Illness08:00 How Mold Hides in the Body11:15 Leaky Gut, MCAS & Chronic Inflammation14:05 Why Mold Recovery Starts at Home17:10 Can Mold Mutate?20:00 Long COVID, Spike Protein & Mold24:00 Root Cause vs. Symptom-Based Medicine28:10 Heavy Metals & Environmental Toxicity31:20 Parasites and Gut Dysbiosis34:30 Are We Oversupplementing?38:15 Pharmaceuticals & Nutrient Deficiencies42:10 Why Healing Requires Fixing the Environment45:20 Have We Never Been Sicker?47:45 The Cholesterol Controversy50:10 The Biggest Lie in Modern Medicine52:30 Where to Find Dr. Michael Biamonte-----------------------------------------------------------------------------------------------

Dr. Jess Peatross trained in conventional medicine and worked as a hospitalist before she started questioning why so many chronically ill patients kept getting worse inside the healthcare system she trusted. Her perspective carries weight because she spent years following every protocol exactly as taught before walking away from hospital medicine entirely.Raised in Huntington, West Virginia during the opioid crisis, she entered medicine believing the system existed to heal people. Instead, she found hospitals driven by billing codes, liability management, and pharmaceutical dependence while patients with chronic illness, autoimmune disease, mold exposure, and chronic pain cycled endlessly through appointments and prescriptions.Dr. Peatross explains what pushed her toward functional medicine, cannabis therapy, and prevention focused care after watching patients improve only after leaving conventional treatment pipelines behind. The conversation tackles physician burnout, chronic illness stigma, healthcare incentives, and the growing collapse of trust between patients and institutions.The discussion also moves into supplements, environmental toxins, ultra processed food, and the uncomfortable economics behind keeping people permanently sick but continuously billable. Dr. Peatross describes the professional backlash that comes with challenging medical orthodoxy while Matthew connects her experience to the broader erosion of public trust across American healthcare.Together they unpack what happens when patients stop believing the system can help them and start searching elsewhere for answers.RELATED LINKSDr. Jess PeatrossInstagramMarshall UniversityBrave New WeedFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

Americans pay roughly three times as much for prescription meds as people in other wealthy nations. But why? Tahir Amin argues it's largely to do with how our patent systems work. He's been on both sides of the issue: He spent a decade as an intellectual property lawyer, helping corporations use patents to protect their bottom lines. Then he moved to India and saw firsthand how the global patent system hampered access to HIV drugs. That led him to shift gears and create an advocacy organization aimed at changing the patent system to make access to medicines more equitable. He chats with Flora about how it all works, and his new book, “Pharma Monopoly.” Read an excerpt from “Pharma Monopoly: The Battle for the Future of Medicines.” Guest: Tahir Amin is a co-author of “Pharma Monopoly: The Battle for the Future of Medicines” and a founder and CEO of Initiatives for Medicine Access and Knowledge (I-MAK).  Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Follow our show on Instagram, TikTok, Facebook, and Bluesky @scifri and sign up for our newsletters. Got a science question that's keeping you up at night? Call us: 877-472-4374 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

Kinsella on Liberty Podcast: Episode 494. This is my interview by Alex Buxeda of at Schweizer Monat [Swiss Monthly; linktree]; recorded June 22, 2026. Youtube shownotes: Stephan Kinsella, patent attorney, legal theorist, and one of the leading critics of intellectual property sits with Alex Buxeda to explore whether ideas can be owned. Starting from first principles, they discuss why Kinsella argues that patents and copyrights are incompatible with property rights, the role of scarcity in economics, innovation without intellectual property, pharmaceutical patents, entrepreneurship, pricing, and the philosophical foundations of ownership. Grok summary: We discussed why intellectual property is fundamentally incompatible with genuine property rights. Stephan Kinsella argued that patents and copyrights are not legitimate property but state-granted monopolies that violate real ownership of scarce, physical resources. He explained that ideas and knowledge are non-scarce and non-rivalrous — one person's use does not prevent another's — so enforcing IP requires aggression against others' tangible property. We explored the flaws in common justifications for patents (especially in pharmaceuticals), the arbitrary nature of IP law, the myth that “creation” grants ownership, and how free competition and open knowledge flows drive far more innovation than government-protected monopolies. Kinsella also addressed the ethics of piracy, the distorting effects of the FDA and tariffs, and why emerging technologies like 3D printing and AI will increasingly undermine IP systems. https://youtu.be/Q4SD8pmpv1U?si=gtx2KN2CcsAbIl5s Related links/publications (Grok assist) For further discussion of the issues raised in this conversation, see the following resources by Stephan Kinsella, grouped by topic: Core Case Against IP & Property Rights Fundamentals Against Intellectual Property (2001/2008) — Kinsella's foundational monograph making the case that patents and copyrights are incompatible with libertarian property rights based on scarcity and homesteading. The Problem with Intellectual Property (2025) — A comprehensive recent paper arguing that IP rights are unjust state-granted monopolies that violate legitimate property rights in scarce resources. Against Intellectual Property After Twenty Years: Looking Back and Looking Forward (2022) — Updated reflections on the original arguments, addressing common objections and developments since 2001. Intellectual Property Rights as Negative Servitudes (2011) — Argues that IP functions as non-consensual negative servitudes on others' physical property, violating true property rights. Another Way to Explain the Problem with IP: Resources v. Knowledge; Ownership v. Possession (2017) — Clear distinction between scarce resources (subject to ownership) and non-scarce knowledge/ideas. The Prior-Later Distinction (2026) — Clarifies the foundational role of first-use (prior appropriation) in property rights theory. Structural Unity of Real and Intellectual Property? (2025) — Examines (and rejects) attempts to unify real and intellectual property conceptually. Scarcity, Ideas, Labor Theory & Creationism Critiques Ideas are Free: The Case Against Intellectual Property (2010) — Explains why ideas and knowledge are non-scarce and why libertarians were mistaken in supporting IP. Libertarian Lockean Creationism (2025) — Critique of the mistaken “creation” theory of property rights often used to defend IP. Locke's Big Mistake: How the Labor Theory of Property Ruined Political Theory Locke's Big Mistake (Transcript) (2013) Hume on Intellectual Property and the Problematic Labor Metaphor (2011) On the Danger of Metaphors in Scientific Discourse (2011) Objectivist Law Prof Mossoff on Copyright; or, the Misuse of Labor, Value, and Creation Metaphors (2008) How We Come to Own Ourselves (2006) — Explains self-ownership and original appropriation, central to why IP conflicts with libertarian property theory. Superabundant Bananas & Property Rights as Normative Support for Possession (2025) — Further clarification on scarcity, superabundance, and the nature of property rights. Pharmaceuticals, FDA & Market Distortions Patents and Pharmaceuticals (2023) Are Patents Needed to Make Up for FDA Kneecapping? (2011) FDA and Patent Reform: A Modest Proposal (2023) Milton Friedman on the Distorting Effect of Patents (2011) Drug Reimportation (2009) — Discussion of reimportation, free trade, and how patents distort pharmaceutical pricing. Tabarrok: Patent Policy on the Back of a Napkin (2012) — Critique of simplistic patent policy arguments. KOL469 | Tabarrok on Patents, Price Controls, and Drug Reimportation Practical & Reform Topics Do Business Without Intellectual Property (2014) How to Improve Patent, Copyright, and Trademark Law (2011) The American Invents Act and Patent Reform (2011) IP Law and Market Failure (2022) Intellectual Nonsense: Fallacious Arguments for IP (2012/2021) — Critique of common fallacious pro-IP arguments. Copyright Absurdities & Other Examples Libraries Prepare to Burn Foreign Books, Courtesy Copyright Law (2011) — Striking example of the absurd real-world effects of copyright enforcement. Historical Libertarian & Objectivist Views on IP Rothbard and the Galambosians (2005) — Discussion of extreme pro-IP views within libertarian circles and Rothbard's perspective. The Galambosians Strike Back (2015) Around This Time I Met the Galambosian (2013) Rand Chose IP: Death Over Life (2025) — Critique of Ayn Rand's strong support for IP. IP: The Objectivists Strike Back (2009) — Response to Objectivist defenses of IP. Why Objectivists Hate Anarchy (2009) — Broader context on Objectivist-libertarian tensions, including IP. Purpose of Law, Schizophrenic State & Broader Theory The Purpose of Law: Justice and Property Rights (2026) The Schizophrenic State (2006) — Classic piece on the contradictory nature of state actions regarding monopolies and competition. Foundational Libertarian Theory Legal Foundations of a Free Society (2023) Disentangling Legal and Economic Concepts (2025) The Title-Transfer Theory of Contract (2024) A Libertarian Theory of Contract (2003) What Libertarianism Is (2009) Recent Audio/Lectures KOL489 | The Problem with Intellectual Property (Audio) (2026) KOL483 | The Economics and Ethics of Intellectual Property (2026) KOL491 | Trying to Persuade Paul Cwik of the Case Against IP KOL253 | Berkeley Fed Soc: Libertarian's Case Against IP KOL469 | Tabarrok on Patents, Price Controls, and Drug Reimportation These resources expand on the core themes of scarcity versus ideas, negative servitudes, pharmaceutical patent issues, market distortions, FDA interactions, practical business strategies, Locke's labor theory mistakes, contract theory, self-ownership, metaphors in discourse, Objectivist views on IP, the purpose of law, and libertarian first principles discussed in the interview. Shownotes (Grok) Podcast Shownotes Episode Title: Stephan Kinsella: Why Intellectual Property is Incompatible with Property Rights Guest: Stephan Kinsella (retired patent attorney & libertarian legal theorist) Host: Alex Buxeda Episode Summary Stephan Kinsella delivers a rigorous, first-principles critique of patents and copyright. He argues that IP is not property at all, but a government-granted monopoly that violates genuine property rights in scarce resources. Drawing on Austrian economics and libertarian ethics, he explains why ideas are non-scarce, why IP slows innovation, and why free markets and competition are superior engines of progress. A clear, uncompromising defense of abolishing intellectual property. Total Runtime: ~1 hour 22 minutes Key Topics & Timestamps 0:00 – Introduction and Practical Market Realities Kinsella begins by noting that entrepreneurs can use strategies like loss leaders and price discrimination, but cartels and monopolies are hard to sustain due to competition and cheating — setting the stage for his deeper critique of state-enforced monopolies like IP. 1:00 – Kinsella's Journey from Pro-IP to Abolitionist As a former patent attorney and lifelong libertarian, Kinsella originally accepted Ayn Rand's defense of IP. After deep study while practicing patent law, he concluded that IP is literally unjustifiable and incompatible with property rights. This realization forced him to refine his understanding of libertarian property theory, relying more heavily on Mises, Rothbard, and Hoppe. 4:22 – Core Argument: Scarcity, Property Rights, and Why Ideas Are Not Property Property rights exist solely to resolve conflicts over scarce, rivalrous resources. Ideas and knowledge are non-scarce — one person's use does not prevent another's simultaneous use. Granting IP rights therefore requires using force against others' legitimate physical property (factories, printers, materials), creating artificial conflict rather than resolving it. IP is not ownership of information; it is a negative servitude on real property. 14:55 – The Pharmaceutical Patent Defense and Why It Fails Kinsella directly refutes the claim that expensive R&D requires patents. High drug costs stem primarily from FDA regulation, not invention. Patents create monopoly pricing and slow knowledge diffusion, which is the true source of long-term progress. He criticizes utilitarian “market failure” arguments, arbitrary patent terms, and the state's schizophrenic approach (granting monopolies via patents while attacking monopolies via antitrust). Free markets naturally reward first movers with temporary profits before competition drives prices down. 31:45 – Arbitrariness of IP and the Myth of “Creation” as a Source of Rights Patent and copyright durations are completely arbitrary....

Researchers have engineered an artificial cell out of chemicals and biomolecules that, at a basic level, can eat, grow, duplicate its own genetic code, and reproduce itself. The cell, dubbed SpudCell, is aimed at creating a chassis that can be adapted to create biological factories for the chemicals humans rely on for modern life, from fuels to pharmaceuticals. But it also raises the question of what it means for something to be “alive.”  Synthetic biologist Kate Adamala joins Host Ira Flatow to talk about the technological advance, the possibilities for the artificial cell, and a nonprofit organization she hopes will allow the SpudCell to spark an innovation in biotechnology. Guest: Dr. Kate Adamala is a synthetic biologist and an associate professor of  genetics, cell biology, and development at the University of Minnesota. Transcripts for each episode are available within 1-3 days at sciencefriday.com. Subscribe to this podcast. Follow our show on Instagram, TikTok, Facebook, and Bluesky @scifri and sign up for our newsletters. Got a science question that's keeping you up at night? Call us: 877-472-4374 Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

In the United States, nearly 70% of people say they want to die at home, yet the majority still die in medical settings, often after receiving care that may not match their goals and values. Closing that gap between preference and reality is at the heart of the work being done by End Well, a nonprofit dedicated to transforming how we think about, plan for, and experience the end of life. "The gap isn't about people wanting the wrong things. It's that our culture and our incentives aren't aligned with helping those wishes actually happen at the end of life,” says Dr. Shoshana Ungerleider, End Well's founder and president.  As Dr. Ungerleider explains to Raise the Line host Michael Carrese, End Well sponsors an annual symposium and year-round activities to bring together clinicians, patients, caregivers, and innovators to improve that alignment. Key steps include earlier integration of palliative care, allowing providers time for listening and goal setting with patients, and normalizing conversations about what matters most to people. This compelling conversation on reframing end of life care also covers how to bring wonder, joy, and hope into end-of-life conversations, and End Well's work to change how death is portrayed in the media. Mentioned in this episode:End Well If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Farla Efros is a senior retail executive and former CEO who built and sold companies before facing her own breast cancer diagnosis. She brings that same operational mindset into a healthcare system that expects patients to manage complexity while they are at their most vulnerable.She was on a client call in Spain when the diagnosis came through. A clear mammogram had missed it. An MRI caught it. Within hours, she was ordering binders, building a plan, and structuring her treatment like a turnaround strategy. Every appointment became a meeting. Every doctor faced an agenda with dozens of questions. She paid out of pocket for PET scans that were denied and hired a third party firm to validate her treatment path when her own doctors resisted outside input. The conversation tracks what happens when a high-functioning executive enters a system built on delay, denial, and fragmentation. Efros describes negotiating for tests, managing physician relationships, and assembling an “executive board” of advisors across conventional and alternative care. She calls the experience “the worst client I ever had,” exposing how administrative burden shifts onto patients and families.The tension sits between what worked for her and what is inaccessible to most. Her approach requires confidence, time, and fluency in navigating power. The system rewards that behavior while quietly failing patients who cannot replicate it. Insurance coverage still left her paying out of pocket. Doctors pushed standard protocols over precision medicine. Survivorship offered little support once treatment ended.This episode examines how cancer care operates as a series of incentives rather than a coordinated system, and why patients are forced to become operators just to get through it.RELATED LINKSFarla EfrosFarla Efros on LinkedInF*ck CancerF*ck Cancer on AmazonAccentureCTOAMPULL QUOTES“I treated cancer like the worst client I ever had.”“They wouldn't approve the test, so I paid for it myself.”“Every appointment was a negotiation.”FEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

With scores of pending lawsuits involving drugmaker and covered entity challenges of how federal and state governments regulate 340B, the courts have become an important arena in the national 340B debate. 340B Health's Vice President of Legal and Policy Amanda Nagrotsky unpacks some of the cases and what they might mean for 340B's future.Courts Wrestle With Issues of Federal and State AuthorityDrug companies have filed about 80 lawsuits challenging state contract pharmacy protection laws. Nagrotsky says drugmakers are arguing these state laws conflict with federal oversight, but most courts so far have ruled that contract pharmacy protection laws fall within a state's ability to regulate drug distribution and delivery. A recent decision from a federal judge in Mississippi was a major win for covered entities because it completely dismissed a drugmaker's challenge to the state's law rather than just ruling on whether to pause enforcement of the law. AbbVie Challenges 340B Patient DefinitionDrugmaker AbbVie is suing the Health Resources & Services Administration (HRSA) directly, arguing that the definition of whom the agency considers a 340B-eligible patient is too broad. AbbVie's own, narrower patient definition would require drug companies to discount far fewer drugs and thus would limit hospital access to 340B savings significantly. The government is asking the court to dismiss the lawsuit on procedural grounds, and 340B Health along with two member hospitals are asking the court to allow them to intervene as defendants and provide additional arguments for why it should throw out the case.Uncertainty Remains Despite GPO, Child Site RulingsFederal district court decisions found that HRSA failed to explain why it adopted a 2013 policy barring certain 340B hospitals' use of group purchasing organizations (GPOs) to make initial purchases for their virtual inventory systems and a 1994 policy establishing registration prerequisites for new 340B hospital outpatient facilities. Although the government opted against appealing the ruling striking down the GPO policy, the underlying prohibition remains in effect, leaving hospitals in limbo as to how HRSA will interpret the law. The government has appealed the child site ruling, and a final decision on that case will have a major impact on how quickly hospitals can use 340B drugs at new child sites.

While Elsevier's most recent Clinician of the Future Report shows increasing adoption of artificial intelligence tools among physicians and nurses, and optimism that they will improve quality of care in the future, a majority raised concerns about trust and reliability. To increase the level of trust, 60% said transparent citations of evidence-based and peer-reviewed research will be key. How to provide that transparency is our focus today as Raise the Line host Lindsey Smith welcomes Elsevier colleagues Rhett Alden and Raman Kaur to guide us through the complexities involved, including the concept of traceability and what role it plays in how AI tools such as Elsevier's ClinicalKey AI are built and deployed.  “Traceability changes the confidence that a clinician has in an AI tool so that they aren't trusting the AI, they're trusting the underlying evidence they're consuming from the AI-assisted platform,” says Raman, who brings years of experience as a primary care practitioner to her work.  It's also important, Rhett adds, to provide additional information, pulled from both the clinician's query and the patient's medical record, to inform clinical thinking. “ClinicalKey AI can be more than a response engine by establishing a larger context to provide a more precise answer for that individual patient.” In this thought-provoking discussion, these experts also provide insights on: Mitigating bias in AI results; Using AI responsibly with sustainability in mind; What type of clinician will benefit most from AI Mentioned in this episode: ClinicalKey AI Clinician of the Future Report If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

In 2020, Emily Mendenhall drove from Washington, DC to Okoboji, Iowa, a town of 800 that swells to 200,000 every summer, and walked into a pandemic that looked nothing like the one dominating national headlines. Inside gas stations and bars, masks marked you as an outsider. In one stop, a man told her family they would not be served if they kept theirs on. Her 6 year old daughter cried, confused. Mendenhall, a medical anthropologist at Georgetown University, did what she always does. She started asking questions. Over months, she interviewed neighbors, former classmates, and local officials, including her own brother in law who helped lead the local COVID response. The result became Unmasked, a case study in how community identity, economics, and politics shaped public health decisions in real time. That work led directly into her latest book, Invisible Illness: A History, from Hysteria to Long COVID, where she tracks a much older problem. Patients with chronic illness, especially women, often fail to meet medicine's demand for proof. Without a clear diagnosis, they lose access to care, insurance coverage, and legitimacy. Mendenhall argues that long COVID did not create this failure. It exposed it.This conversation centers on how healthcare systems reward certainty and punish complexity. Long COVID clinics send patients to 17 specialists without resolution. Insurance structures require diagnoses that many conditions cannot provide. Medical training still struggles to integrate trauma, mental health, and chronic disease into a coherent model of care.Mendenhall brings lived experience into the conversation. After COVID, she dealt with months of fatigue and escalating anxiety that altered her baseline health. She does not claim the label of long COVID, but she understands how quickly the system becomes harder to navigate once symptoms stop fitting clean categories. The stakes are not theoretical. In the United States, access to healthcare, disability benefits, and treatment still depends on whether a condition can be measured, coded, and reimbursed. For millions living with invisible illness, the burden of proof becomes the illness itself.RELATED LINKSEmily MendenhallInvisible Illness: A History, from Hysteria to Long COVIDScience PoliticsGeorgetown UniversityFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

It's been one year since the U.S. Centers for Disease Control and Prevention, in an unprecedented move, dismissed all the members of its Advisory Committee on Immunization Practices (ACIP), kicking off what would turn out to be a very concerning and busy year for infectious disease specialists.  We're going to recap this turbulent period – which includes a resurgence of measles, an unusually rough flu season, the emergence of a new COVID strain and outbreaks of hantavirus and Ebola – with Dr. William Schaffner, one of the country's most frequently quoted medical experts on infectious disease, vaccination, and public health. As a member of ACIP for decades, Dr. Schaffner brings unique insight into the dismantling of the committee and the distrust of vaccines that lies at the root of the changes. As he explains to Raise the Line host Lindsey Smith, while many vaccine critics are beyond reach, there are those he describes as vaccine hesitant that may be persuadable if the right approach is taken. “Beyond providing facts, we have to listen to them and respond to their concerns and make them feel comfortable. Information is fundamental, but behavior change only comes with a change in attitude.” Tune in for a wealth of wisdom and context that includes observations on: What's complicating containment of the Ebola outbreak; Challenges in public health communication in the current social media environment; What grade health authorities should get on their response to the hantavirus outbreak. Mentioned in this episode:Vanderbilt University School of Medicine If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

On today's Good Day Health Show - ON DEMAND…On this special episode of Good Day Health, host Doug Stephan welcomes back Elizabeth Miller for a discussion about healthy, sustainable weight management and the benefits of Calotren. Elizabeth explains how Calotren works as a natural weight-loss supplement designed to support the body's overnight repair process, helping users achieve steady, long-term results without the harsh side effects often associated with pharmaceutical weight-loss drugs. The conversation explores Calotren's reported success rate and safety profile, while comparing its approach to popular prescription medications currently on the market. Elizabeth also discusses additional benefits users may experience, including improved sleep quality, support for lean muscle retention during weight loss, healthier-looking skin, and reduced cravings. Throughout the episode, she emphasizes the importance of gradual, sustainable weight loss rather than quick fixes, sharing why consistency often leads to better long-term outcomes.  To learn more about Calotren and take advantage of the anniversary savings, visit TopLoss.com or call 833-TOP-LOSS. When ordering online, click “Shop Radio Sale” and use promo code DOUG at checkout for additional savings and free shipping.For more on Good Day Health…Website: GoodDayHealthShow.comSocial Media: @GoodDayNetworks

At 25, Jace Yawnick was building a career in health and wellness sales, chasing growth, status, and the usual young adult fantasy of getting somewhere fast. Then his body stopped cooperating. Fatigue turned into chemotherapy. The diagnosis was primary mediastinal B cell non Hodgkin lymphoma, and the rest of his life split into before and after. Now in remission, he talks about cancer the way people actually live it, not the way nonprofits package it. He gets into survivorship, mental health, young adult isolation, and the deadening absurdity of prior authorization. One of the sharpest parts of the conversation lands on a simple American insult disguised as policy: treatment innovation means very little when insurance can still deny the scan, the drug, or the next step. Jace has seen that firsthand, including during routine monitoring after active treatment. This episode tracks what happens when a young cancer patient becomes a public voice and refuses to play mascot. It covers oncology, insurance, remission, advocacy, and the long mental hangover that follows survival. It also names the part too many institutions dodge: the system works great right up until it doesn't, and when it fails, patients get handed the bill, the panic, and a camera if they want anyone to care. RELATED LINKSJace Beats CancerJace Yawnick on LinkedImConquer Cancer ArticleCURE Today ArticlePyure BrandsFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

At 20 years old, newly arrived from Puerto Rico and trying to build a future in science, Benjamin Suarez Jimenez found himself sitting in front of two senior faculty members accused of plagiarism. He knew the material. He had done the work. His mistake came from failing to cite class notes during an exam because nobody had told him that was expected. In a matter of minutes, he watched what felt like his entire career flash before him.On this episode of Standard Deviation, host Oliver Bogler examines the hidden architecture of academic science through the experiences of Dr. Benjamin Suarez Jimenez, Assistant Professor at the University of Rochester and a neuroscientist studying PTSD, anxiety, trauma, and spatial cognition through virtual reality and video game environments.Benjamin traces his path from Puerto Rico to the mainland United States, through the NIH, Columbia University, and eventually to leading his own laboratory. Along the way, he encountered a series of barriers that had little to do with scientific ability and everything to do with access to unwritten rules. From academic gatekeeping to grant writing expectations, he learned that success in biomedical research often depends on knowledge that never appears in a textbook.Oliver explores how those invisible obstacles shape careers, influence research funding, and determine who gains access to opportunity. The conversation also examines the Justice, Equity, Diversity, and Inclusion Program at the Life Science Editors Foundation, which pairs scientists from underrepresented backgrounds with experienced scientific editors. Through that mentorship, Benjamin transformed a critical grant proposal into a successful pilot award that helped launch an NIH R01 application.The discussion extends beyond one scientist's experience. Benjamin describes helping a former mentee navigate dissertation roadblocks that threatened her graduation, illustrating how institutional bureaucracy can delay careers and discourage talented researchers. Together, they explore the hidden administrative burden, cultural barriers, and bias that many scientists carry alongside their research, and what happens when someone who receives support turns around and opens the door for others.RELATED LINKSLife Science Editors FoundationBenjamin Suarez Jimenez LabDr. Benjamin Suarez JimenezBenjamin Suarez JimenezFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

"Do nothing for us without us." According to today's guest Robyn Bussey, that operating principle is the basis for effective community health work. "You don't go into a community and dictate. You go and listen and trust and be a partner," she adds. As you'll learn in this enlightening conversation, Bussey is following that approach in her current work as Just Health Director at the Partnership for Southern Equity, an Atlanta-based nonprofit advancing racial equity and shared prosperity across the South.  On this episode of Raise the Line from Elsevier, Bussey provides illuminating  examples of community-rooted work in South Fulton County and rural Georgia, and explains why community health workers may be the most underutilized asset in addressing health disparities. This wide-ranging interview with host Michael Carrese also explores: Bussey's candid perspective on what happened to the surge of interest in health equity that occurred during COVID; Why life expectancy gains in many Southern states have lagged behind the rest of the country; Her advice to students and early-career clinicians about where they're needed most.   Mentioned in this episode:  Partnership for Southern Equity If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

Comment on the Show by Sending Mark a Text Message.Have you ever felt that your hard work and achievements were overshadowed by systemic bias in the workplace? Join Mark Carey in this gripping episode of the Employee Survival Guide® as he delves into the troubling case of Lauren Landhoff against Zytus Pharmaceuticals, a stark illustration of constructive discharge and the insidious nature of gender discrimination in corporate America. Lauren, a talented executive who built a thriving business division from the ground up, found herself facing exclusion from leadership roles despite her undeniable success. This episode unpacks the layers of discrimination that often lurk beneath the surface of a seemingly meritocratic environment. Mark and his co-host dissect the details of Lauren's lawsuit, revealing how her value was systematically undermined by male executives who resorted to derogatory comments and exclusionary practices. The discussion raises critical questions about the role of human resources, often seen as protectors of corporate interests rather than champions of employee rights. The narrative serves as a wake-up call for anyone navigating the complexities of employment law, especially those facing hostile work environments, retaliation, or discrimination of any kind. Throughout the episode, listeners will gain valuable insights into the importance of documenting workplace interactions and creating a paper trail, especially when dealing with employment disputes. The conversation emphasizes the necessity for employees to advocate for themselves, understand their rights, and recognize the signs of systemic bias that can lead to constructive discharge. With a focus on employee empowerment, this episode equips you with the tools to navigate your career with confidence, whether you're negotiating severance packages, facing performance reviews, or dealing with workplace bullies. As we explore Lauren's story, we also touch on broader themes of workplace culture, gender discrimination, and the challenges women face in leadership roles. This episode is not just about one individual's struggle; it's a rallying cry for all employees to stand up against discrimination and advocate for a more equitable work environment. Join us as we break down the barriers of silence surrounding these issues and provide actionable strategies for survival in today's corporate landscape. Don't miss this enlightening discussion that promises to inspire change and equip you with essential knowledge for your career journey. Tune in to the Employee Survival Guide® and empower yourself with the insights you need to thrive in a world where constructive discharge and discrimination still exist.  If you enjoyed this episode of the Employee Survival Guide please like us on Facebook, X and LinkedIn.  We would really appreciate if you could leave a review of this podcast on your favorite podcast player such as Apple Podcasts and Spotify. Leaving a review will help other employees find the Employee Survival Guide.  For more information, please contact our employment attorneys at Carey & Associates, P.C. at 203-255-4150, www.capclaw.com.Disclaimer:  For educational use only, not intended to be legal advice. 

Dr. Sarah Matt trained as a burn surgeon, working in a field where patients arrive with catastrophic injuries and survival depends on speed, skill, and resources. She left the bedside after confronting a limit that medicine does not like to admit. One physician can only see so many people in a day. The system surrounding those patients decides the rest. She moved into health technology, held leadership roles in startups, and built global infrastructure at Oracle to scale care across populations. Then she watched billions of dollars in digital health and AI initiatives stall out when they hit real clinical environments.This episode follows that pivot from surgeon to strategist and back into direct patient care in rural New York, where she now treats uninsured patients, migrant workers, and communities pushed to the margins. The conversation centers on a persistent failure across healthcare systems. Products get built for regulators, executives, and investors instead of the people who use them. The result shows up in failed adoption, broken workflows, prior authorization delays, and rising physician burnout.The discussion cuts through health policy language and lands on lived consequence. The system rewards speed over usability, scale over trust, and compliance over care. Patients absorb the fallout. Physicians carry the liability. The incentives remain intact.RELATED LINKSDr. Sarah MattThe Borderless Healthcare RevolutionThe Clinical RealistJessica FedererSovatoFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.

What happens when counterfeit pharmaceuticals go digital? In this episode of Power Supply, Vinny Minhas, VP and Head of Sales at an AI-powered brand protection company, j joins the conversation to explore how technology is reshaping the fight against counterfeit drugs. From the rapid increase in counterfeit medications and hidden online marketplaces to the growing role of AI in identifying suspicious activity, Vinny shares how brands, platforms, and industry partners are working together to protect patients and preserve trust. He also explains how social media platforms, messaging apps, and other digital channels are changing the way counterfeit pharmaceuticals are marketed and sold. If you've ever wondered how counterfeit products find their way into healthcare, this episode offers a timely look at one of the industry's fastest-evolving challenges. Once you complete the interview, jump on over to the link below to take a short quiz and download your CEC certificate for 0.5 CECs! – https://www.flexiquiz.com/SC/N/ps18-06 #PowerSupply #Podcast #AHRMM #HealthcareSupplyChain #SupplyChain #CounterfeitPharmaceuticals #Trust #PatientSafey #Digital #BrandProtection

How Young Lupus Patients Can Cope With Physical And Mental Health Issues Lupus is a chronic condition where a person's immune system attacks their healthy tissue. But while the physical toll is obvious, the extreme mental health issues that can arise are too often ignored. Our experts this week explain the connection between lupus and mental health, and discuss a program that's finally addressing these issues in young patients. Guests:  Natoshia Cunningham, Red Cedar Distinguished professor & associate professor in the Department of Family Medicine, Michigan State University, founder, TEACH Program Isabella Colindres, consumer advocate, TEACH Program Host and Producer: Kristen Farrah   Genetic Testing Is The Key To Optimizing Your Health Health optimization has become a huge focus in recent years, but many people are skipping the foundational step – genetic testing. Knowing the core of who you are helps direct you to the best medicine, diet, and exercise for you. Our expert explains the benefits of genetic testing and how to make sure you're getting quality results. Guest: Dr. Puya Yazdi, Chief Science & Medical Officer, SelfDecode Host: Greg Johnson Producer: Kristen Farrah Facebook: ingoodhealthpodX: @ ingoodhealthpodIG: @ingoodhealthpodYouTube: @ingoodhealthpodSpotify Apple Podcast In Good Health PodcastSubscribed to the newsletterFull ArchiveContact UsBecome an Affiliate Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

How Young Lupus Patients Can Cope With Physical And Mental Health Issues Lupus is a chronic condition where a person's immune system attacks their healthy tissue. But while the physical toll is obvious, the extreme mental health issues that can arise are too often ignored. Our experts this week explain the connection between lupus and mental health, and discuss a program that's finally addressing these issues in young patients. Guests: Natoshia Cunningham, Red Cedar Distinguished professor & associate professor in the Department of Family Medicine, Michigan State University, founder, TEACH Program; Isabella Colindres, consumer advocate, TEACH Program Host and Producer: Kristen Farrah   Facebook: ingoodhealthpodX: @ ingoodhealthpodIG: @ingoodhealthpodYouTube: @ingoodhealthpodSpotify Apple Podcast In Good Health PodcastSubscribed to the newsletterFull ArchiveContact UsBecome an Affiliate Hosted by Simplecast, an AdsWizz company. See pcm.adswizz.com for information about our collection and use of personal data for advertising.

As concerns escalate about the deadly Ebola virus outbreak in Africa, we bring you the unique insights of Dr. Peter Piot, a renowned microbiologist who co-discovered the virus 50 years ago during the first recorded outbreak of the disease. His on-the-ground account of that crisis was provided to us in April before the current outbreak was declared, but it contains valuable historical perspective and shares lessons learned that he carried forward in his consequential career.  “What I saw from the beginning is the most important thing is to listen to people and that you need to act fast to save lives, before you have the evidence you would like to have.”    He followed his contributions on Ebola by diving into the fight against HIV/AIDS, eventually reshaping global response in leadership roles at the World Health Organization and United Nations. As he shares with host Lindsey Smith, the learnings in that case were more pragmatic than scientific. “We had to redefine HIV/AIDS not as a medical problem but as an economic and security problem in order to get it on the political agenda.”  Tune in for a fascinating episode that takes you from the gritty frontlines of public health crises to the battles for funding and attention in the halls of power as Dr. Piot shares what it actually takes to move the world to respond effectively to health threats. Mentioned in this episode: London School of Hygiene & Tropical Medicine If you like this podcast, please share it on your social channels. You can also subscribe to the series and check out all of our episodes at www.osmosis.org/podcast

In the late 1980s, a child exposed to fallout from the Chernobyl disaster lay in a hospital bed while doctors told his family there were no clear answers and no reliable path forward. Decades later, that same child, Yan Leyfman, walks into exam rooms as a hematology oncology fellow, expected to deliver clarity inside a system that still runs on delay, uncertainty, and institutional self preservation.This episode traces the throughline from early life shaped by radiation exposure and hospice level uncertainty to a career inside academic medicine, translational research, and oncology media. Yan built his identity around survival and usefulness, moving from patient to physician while carrying the memory of what it feels like to sit on the other side of the table. He helped launch MedNews Week during the COVID crisis to push back on misinformation and expand access to medical knowledge, stepping into a public role while still in training.The conversation stays grounded in the friction between personal narrative and system reality. Clinical training demands efficiency, hierarchy, and emotional distance. Cancer care demands time, clarity, and human connection. Those forces collide in real patient encounters where prior authorization delays, insurance barriers, and fragmented care pathways shape outcomes as much as any treatment protocol.Yan speaks openly about mentorship, belonging, and the drive to make meaning out of survival. The discussion pushes further into what the healthcare system actually rewards, what it quietly strips away, and how quickly empathy can erode under institutional pressure. The episode also examines the role of medical media, where education, industry influence, and narrative control often blur together.This is a conversation about identity under construction, about what happens when someone who remembers powerlessness steps into a role that carries authority, and about whether that memory can survive long enough to change anything.RELATED LINKSYan Leyfman on LinkedInYan Leyfman on InstagramSurviving ChernobylFEEDBACKLike this episode? Rate and review Out of Patients on your favorite podcast platform. For guest suggestions or sponsorship email podcasts@matthewzachary.comSee Privacy Policy at https://art19.com/privacy and California Privacy Notice at https://art19.com/privacy#do-not-sell-my-info.